Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom

NCT ID: NCT00757614

Last Updated: 2013-08-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

14000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This study is looking at genetic susceptibility to cancer and interactions between genes and the environment in patients with cancer in East Anglia, Trent, or West Midlands of the United Kingdom.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

* To obtain epidemiological information and biological material on a population-based series of cancer cases, including malignant melanoma, lymphoma, bladder, kidney, esophageal, and pancreatic cancer, and brain tumors.
* Identify novel cancer susceptibility genes, by comparison of genotype frequencies in cases with the corresponding frequencies in large control series.
* To estimate the age and sex-specific risks associated with variants in predisposition genes.
* To evaluate interactions between polymorphisms in predisposition genes and potential lifestyle risk factors.

OUTLINE: This is a multicenter study.

Patients complete a detailed epidemiological questionnaire that includes information on education, occupation, smoking habits, alcohol consumption, height, weight, reproductive history (age at menarche, age at pregnancies, parity, and age at menopause), oral contraceptive use, hormone replacement therapy use, family history of cancer, and past medical history.

Blood samples are collected from patients. DNA is extracted from these blood samples, from samples collected from cancer-free control participants in MREC-SEARCH-CONTROL, and from additional controls through the European Prospective Investigation of Cancer (EPIC) study (a population-based study of diet and health based in Norfolk, East Anglia). DNA samples are analyzed for polymorphisms of low penetrance cancer susceptibility genes.

In addition to the cancer patients recruited for this study, patients with breast, ovarian, endometrial, colorectal, and prostate cancer are recruited for the following related clinical trials: MREC-SEARCH-BREAST, MREC-SEARCH-OVARIAN, MREC-SEARCH-ENDOMETRIAL, MREC-SEARCH-COLORECTAL, and MREC-SEARCH-PROSTATE.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bladder Cancer Brain and Central Nervous System Tumors Esophageal Cancer Intraocular Melanoma Kidney Cancer Lymphoma Melanoma (Skin) Pancreatic Cancer Transitional Cell Cancer of the Renal Pelvis and Ureter

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

AIDS-related lymphoma cutaneous lymphoma adult Hodgkin lymphoma adult non-Hodgkin lymphoma intraocular lymphoma adult T-cell leukemia/lymphoma primary central nervous system non-Hodgkin lymphoma primary central nervous system Hodgkin lymphoma noncutaneous extranodal lymphoma adult astrocytic tumors adult brain stem glioma adult choroid plexus tumor adult craniopharyngioma adult embryonal tumor adult ependymal tumors adult meningeal tumor adult oligodendroglial tumors adult pineal parenchymal tumor adult brain tumor intraocular melanoma bladder cancer clear cell sarcoma of the kidney congenital mesoblastic nephroma esophageal cancer melanoma pancreatic cancer peripheral primitive neuroectodermal tumor of the kidney renal cell carcinoma rhabdoid tumor of the kidney transitional cell cancer of the renal pelvis and ureter

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DNA analysis

Intervention Type GENETIC

polymorphism analysis

Intervention Type GENETIC

laboratory biomarker analysis

Intervention Type OTHER

questionnaire administration

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Diagnosed with bladder cancer, kidney cancer, esophageal cancer, pancreatic cancer, brain cancer, malignant melanoma, or lymphoma within the past 5 years
* Identified through the Cancer Research Network OR through the cancer registry serving any of the following geographic regions of the United Kingdom:

* East Anglia
* West Midlands
* Trent

PATIENT CHARACTERISTICS:

* Identified by the patient's general practitioner as fit to contact for this study
* No serious mental illness or retardation

PRIOR CONCURRENT THERAPY:

* Not specified
Minimum Eligible Age

18 Years

Maximum Eligible Age

69 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cancer Research UK

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Paul Pharoah, MD

Role: STUDY_CHAIR

Cancer Research UK

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Cambridge Cancer Research UK

Cambridge, England, United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Contact Person

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MREC-SEARCH-CANCER

Identifier Type: -

Identifier Source: secondary_id

MREC-07/MRE05/17

Identifier Type: -

Identifier Source: secondary_id

CDR0000598879

Identifier Type: -

Identifier Source: org_study_id